EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, SONN: Sonnet Biotherapeutics Holdings Inc

11 Nov 25 15:59
LAST:

4.610

CHANGE:
 0.15		OPEN:
4.360		HIGH:
4.635		ASK:
0.000		VOLUME:
464.1K
CHG(%):
3.36		PREV:
4.460		LOW:
3.720		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
11 Nov 254.3604.6353.7204.610464.1K
10 Nov 255.0405.1384.4104.460537.9K
07 Nov 254.1004.9804.0604.870795.5K
06 Nov 254.4004.6584.0204.220540.4K
05 Nov 253.5004.7203.2104.5501.48M
04 Nov 254.0404.0703.1203.200922.3K
03 Nov 254.8504.9903.9854.030612.0K
31 Oct 254.8705.1604.6855.020519.3K
30 Oct 254.7305.0004.5304.700432.0K
29 Oct 254.8905.0474.4204.750822.0K

COMPANY PROFILE

Name:Sonnet Biotherapeutics Holdings Inc
About:Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.
Sector:Healthcare
Industry:Biotechnology
Address:100 Overlook Center, Princeton, NJ, United States, 08540
Website:https://www.sonnetbio.com
CUSIP:15930P503
CIK:0001106838
ISIN:US83548R1059
FIGI:BBG000BVZ4N6
LEI:5493002WX622LZQC4F93

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:4.541.5%
MA10:4.443.8%
MA20:4.375.5%
MA50:4.742.8%
MA100:4.287.7%
MA200:2.8163.8%
STO9:71.94
STO14:53.21
RSI14:55.83
WPR14:-46.79
MTM14:0.17
ROC14:0.04 
ATR:0.86 
Week High:5.1411.5%
Week Low:3.1247.8%
Month High:5.8526.9%
Month Low:3.1263.8%
Year High:19.30318.7%
Year Low:1.08326.9%
Volatility:61.70 

RECENT SPLITS

Date Ratio
30 Sep 20241-8
01 Sep 20231-22
19 Sep 20221-14
02 Apr 20201-26
19 May 20171-10
25 May 20121-2
23 Mar 20112-1
17 Jul 20081-10